Results 141 to 150 of about 17,588 (197)

HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES. [PDF]

Retina
Vempuluru VS, Raval V, Kaliki S.
europepmc   +1 more source

FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Liu Y, Nashed J, Barone AK, Yuan M, Amatya AK, Xiang Y, Zhao H, Bi Y, Pegues MA, Miller CP, Lane AR, Mixter BD, Tang S, Pazdur R, de Claro RA, Larkins E.   +15 more
europepmc   +1 more source

Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Khan SM, Abboud I, Elhusseiny AM, Elhusseiny AM.   +3 more
europepmc   +1 more source

Comment on: Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Rani T, Mandal R, Bandyopadhyay A.
europepmc   +1 more source

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort. [PDF]

ESMO Open
Gobbini E, Diallo MH, Clément-Duchene C, Chouaid C, Hiret S, Audigier-Valette C, Bizieux A, Debieuvre D, Quantin X, Le Guen Y, Lemoine A, Falchero L, Remon-Masip J, Bosquet L, Pérol M, Girard N.   +15 more
europepmc   +1 more source

Retinal organoid screening reveals ABT-737 and luminespib as potential agents against a cone- precursor-derived subtype of retinoblastoma. [PDF]

Mol Ther Oncol
Kelk J, Rozanska A, Sotiriadou E, Astley D, Hussain R, Unsworth A, Gangar A, Robinson A, Queen R, Coxhead J, Steel DH, Armstrong L, Parulekar M, Hardcastle I, Veal GJ, Lako M.   +15 more
europepmc   +1 more source

NUDT1 drives osteosarcoma progression and serves as a robust predictor of clinical outcomes. [PDF]

Cancer Cell Int
Zhang Z, Wan L, Ai K, Liu J, Tang X, Duan Z, Chen R.   +6 more
europepmc   +1 more source